Position in ENGN
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$264,241
+$2,209 QoQ
Shares Held
38,802
+33.7% QoQ
Ownership
0.058%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2024
9 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in ENGN Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026GEODE CAPITAL MANAGEMENT, LLC holds $21,877,764,044 across 520 Biotechnology names.
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
6,017,848 | $2,989,245,636 | |
| 2 | REGN |
Regeneron Pharmaceuticals, Inc.
|
2,625,810 | $1,637,297,566 | |
| 3 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
2,635,840 | $793,466,914 | |
| 4 | RVMD |
Revolution Medicines, Inc.
|
3,942,676 | $738,384,360 | |
| 5 | MRNA |
Moderna, Inc.
|
9,710,335 | $680,014,759 | |
| 6 | INCY |
Incyte Corp
|
4,750,735 | $538,543,319 | |
| 7 | RPRX |
Royalty Pharma plc
|
8,058,048 | $451,814,751 | |
| 8 | INSM |
INSMED Inc
|
4,220,155 | $449,952,925 |
All Filings in ENGN
Export CSV
9 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $264,241 | 38,802 | Shares | Defined | 2026-05-15 | |
| 2025-12-31 | $262,032 | 29,018 | Shares | Defined | 2026-02-09 | |
| 2025-09-30 | $198,192 | 29,018 | Shares | Defined | 2025-11-12 | |
| 2025-06-30 | $105,625 | 29,018 | Shares | Defined | 2025-08-08 | |
| 2025-03-31 | $130,000 | 29,018 | Shares | Defined | 2025-05-13 | |
| 2024-12-31 | $192,969 | 29,018 | Shares | Defined | 2025-02-12 | |
| 2024-09-30 | $181,605 | 27,516 | Shares | Defined | 2024-11-12 | |
| 2024-06-30 | $259,475 | 27,516 | Shares | Defined | 2024-08-09 | |
| 2024-03-31 | $273,335 | 16,126 | Shares | Defined | 2024-05-13 | |
| No filing history on record for this holder in this stock. | ||||||